Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - Heng Rui Medicine announced the inclusion of several drugs in the national medical insurance directory, which is expected to positively impact sales, although the exact effect on the company's performance is currently indeterminate [1] Group 1: Drug Inclusion in National Medical Insurance - The following drugs have been newly included in the national medical insurance directory: injection of Rukang Qumatuozhuzhantang, Appleseed Famitinib capsules, injection of Funachizhu single antibody, and several others [1] - New indications for injection of Karilizhu single antibody, Fluorozolpali capsules, and Fumaric acid Tejilidin injection have also been successfully added to the national medical insurance directory [1] - The renewal of the following drugs has been successful, allowing them to remain in the national medical insurance directory: Malate Pyrotinib tablets, Hecoropag Ethanolamine tablets, and several others [1] Group 2: Financial Impact - The total sales revenue for the aforementioned drugs is estimated to be approximately 8.66 billion yuan for the year 2024 [1] - For the first three quarters of 2025, the estimated sales revenue for these drugs is around 7.55 billion yuan [1] - The inclusion of these drugs in the national medical insurance directory is expected to facilitate sales, although the specific impact on the company's operational performance remains uncertain [1]

泽璟制药公告称，2025年12月7日，公司自主研发的盐酸吉卡昔替尼片通过国家医保谈判，被纳入《国 家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，将于2026年1月1日起执行，协议有效期 至2027年12月31日。该药品为1类新药，用于治疗骨髓纤维化等，已获多项指南推荐。其治疗重度斑秃 适应症申请已获受理，治疗活动性强直性脊柱炎达主要疗效终点。此次纳入医保利于销售，对长期经营 有积极影响，预计短期内不影响业绩。 ...

Core Viewpoint - The announcement by Zhixiang Jintai (688443.SH) regarding the inclusion of its self-developed drug, Saliqi monoclonal antibody injection (Jinlixi), in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List is a significant development that is expected to positively impact the company's long-term operational performance [1] Group 1: Drug Development and Market Impact - The drug is classified as a Class I biological product and is intended for adult patients with moderate to severe plaque psoriasis and adult patients with ankylosing spondylitis who have inadequate response to conventional treatments [1] - The new drug list will officially take effect on January 1, 2026, which is anticipated to facilitate market promotion and future sales of the drug [1] Group 2: Financial Implications - Inclusion in the medical insurance directory is expected to have a positive effect on the company's long-term operating performance [1] - However, the actual sales will be influenced by various factors, including the medical insurance payment standards and reimbursement details as per the information published by the National Healthcare Security Administration, indicating some level of uncertainty [1]

Core Viewpoint - The National Medical Insurance Drug List for 2025 has been officially published, with Yiling Pharmaceutical's innovative drug Qifang Nizhong Pian being included for the first time [1] Group 1: Drug Approval and Market Entry - Qifang Nizhong Pian is an innovative traditional Chinese medicine specifically indicated for the treatment of persistent allergic rhinitis, addressing a clinical gap in medication [1] - The drug received approval from the National Medical Products Administration in January 2025 and was registered by the Macao Special Administrative Region's government on July 12, 2025, marking it as the first innovative traditional Chinese medicine approved in Macao [1]

从今日举行的2025创新药高质量发展大会现场获悉，恒瑞医药共10款产品首次被纳入新版国家医保药品 目录，覆盖肿瘤、代谢、心血管疾病、免疫系统疾病、眼科等多个领域，具体包括注射用瑞康曲妥珠单 抗、硫酸艾玛昔替尼片、夫那奇珠单抗注射液、注射用瑞卡西单抗、注射用磷罗拉匹坦帕洛诺司琼、瑞 格列汀二甲双胍片(I)/(II)、苹果酸法米替尼胶囊、醋酸阿比特龙片（II）、盐酸伊立替康脂质体注射液 （II）、全氟己基辛烷滴眼液。 ...

Core Viewpoint - The company reported a significant decline in sales and profits for the first half of 2025, with a focus on adapting to market challenges and enhancing product offerings to stabilize its business performance [1][2][3][4] Group 1: Financial Performance - The company achieved sales revenue of approximately HKD 21.47 billion, a year-on-year decrease of about 35.7% [1] - Profit attributable to equity holders was approximately HKD 283.5 million, down about 58.7% year-on-year [1] - Earnings per share were HKD 0.0962, with an interim dividend of HKD 0.05 per share [1] Group 2: Business Segments Infusion Business - Infusion sales volume decreased to approximately 715 million bottles (bags), a decline of 37% year-on-year, with sales revenue of HKD 1.199 billion, down 45% [1] - The company is focusing on product matrix development and digital transformation to enhance market positioning [1] Injectable Business - Ampoule water needle sales volume reached 17.818 million units, a year-on-year increase of 7%, but sales revenue fell by 57% to HKD 157 million [2] - Notable growth in specific products: Methylcobalamin injection sales increased by 61%, and Urapidil hydrochloride injection sales rose by 28% [2] Oral Formulations - Oral formulations achieved sales of HKD 296 million, a year-on-year increase of 16% [2] - New products contributed significantly, with sales of specific items like Rosuvastatin calcium tablets increasing by 32% [2] API Business - API sales amounted to HKD 361 million, a decline of 9.6% year-on-year, with caffeine sales down 15% [3] - The company is enhancing international collaborations and product registrations to mitigate market challenges [3] Export Business - The company reported a 42% increase in export volume for infusions, with significant growth in ampoule water needle and oral formulation exports [3] - The total export sales reached RMB 100.45 million, reflecting a 42% year-on-year increase [3] Packaging Materials - Sales of pharmaceutical packaging materials reached HKD 101 million, a year-on-year increase of 7.1% [4] - The company is focusing on enhancing its product offerings to meet market demands [4]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5][13]. Core Insights - The company reported a revenue of 950 million yuan for the first half of 2025, with a net loss of 145 million yuan [2]. - The commercialization year has begun, with sales starting to ramp up. The company has three products approved for sale: Jiatailai (TROP2 ADC), Ketailai (PD-L1 monoclonal antibody), and Datailai (Cetuximab) [3]. - The company has a strong clinical pipeline, with Jiatailai's core clinical layout entering a harvest period, and several key indications in various stages of clinical trials [4]. Financial Performance - The company is expected to achieve revenues of 2.325 billion yuan, 3.668 billion yuan, and 5.352 billion yuan for the years 2025, 2026, and 2027 respectively, showing significant growth compared to previous forecasts [5]. - The projected net profit for 2027 is 380 million yuan, indicating a turnaround from previous losses [5]. - The revenue growth rates are projected at 20.29%, 57.74%, and 45.91% for the years 2025, 2026, and 2027 respectively [10]. Clinical Development - The company has a robust pipeline with several products in various stages of clinical development, including A166 (HER2 ADC) in NDA stage and A400 (RET inhibitor) in registration clinical stage [4]. - The company is expanding its market reach, with products already covering 30 provinces and over 2000 hospitals [3]. Market Potential - The inclusion of Jiatailai, Ketailai, and Datailai in the basic medical insurance directory is expected to accelerate sales growth [3]. - The market potential for TROP2 ADC in breast and lung cancer is significant, with comprehensive coverage of patients anticipated upon completion of ongoing clinical trials [3].

Core Viewpoint - The implementation plan for the comprehensive reform of drug, medical device, and cosmetic regulation in Hainan Province aims to promote high-quality development of the pharmaceutical industry through various supportive measures for innovative drugs and medical devices [1] Group 1: Support for Innovative Drugs and Devices - The plan includes timely updates to the "Hainan Province Innovative Drug and Device Product Directory," allowing new drugs, first-generic drugs, and generics that pass quality and efficacy consistency evaluations, as well as certain classes of medical devices, to be included for procurement by medical institutions [1] - There is an emphasis on accelerating the use of innovative drugs and devices in hospitals by establishing a long-term mechanism for regular meetings of pharmacy, device management, and pharmacotherapy committees in public hospitals [1] - The initiative aims to facilitate the inclusion of innovative drugs and devices in the national medical insurance negotiations, providing guidance to companies to help eligible products enter the insurance directory [1] Group 2: Pricing and Market Access - A mechanism for the formation of initial pricing and full-cycle price management for innovative medical devices will be established, promoting rapid online trading through price negotiation between supply and demand parties for devices without listed prices [1]